Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study-Reference-Cited by-同舟云学术

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Published:2011-09 Issue:9 Volume:12 Page:852-861
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gelmon Karen A,Tischkowitz Marc,Mackay Helen,Swenerton Kenneth,Robidoux André,Tonkin Katia,Hirte Hal,Huntsman David,Clemons Mark,Gilks Blake,Yerushalmi Rinat,Macpherson Euan,Carmichael James,Oza Amit

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair;Ashworth;J Clin Oncol,2008

2. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition;McCabe;Cancer Res,2006

3. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase;Bryant;Nature,2005

4. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1;Menear;J Med Chem,2008

5. Inhibition of poly (ADP-ribose) polymerase in tumours from BRCA mutation carriers;Fong;N Engl J Med,2009

Cited by 998 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis;Clinical & Experimental Metastasis;2024-09-04

2. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations;npj Precision Oncology;2024-07-31

3. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

4. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer;Frontiers in Oncology;2024-07-22

5. The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer;Genes;2024-07-22